Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD ...

Truist analyst Joon Lee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $90 and keeps a Buy rating on the shares.

NEW YORK, NY / ACCESS Newswire / March 3, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to ...

Intellia Therapeutics reported better-than-expected results for the fourth quarter thanks to a boost in its collaboration ...

Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) came out with a strong set of yearly numbers that could potentially lead to a re-rate of the stock. Revenues were better than expected, with US$58m in revenue ...

Intellia Therapeutics Inc. is shaking up its Cambridge and Waltham real estate footprints. The gene-editing company h as ...

Intellia Therapeutics (NTLA) stock rises as company delivers promising Q4 2024 results with encouraging pipeline updates.

Fintel reports that on February 28, 2025, JP Morgan downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from ...

Handelsbanken Fonder AB lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & ...

Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its target price reduced by Barclays from $55.00 to $26.00 in a report published on Friday,Benzinga reports. Barclays currently has an overweight ...

Using CRISPR/Cas9 gene-editing technology, Intellia Therapeutics develops gene-editing treatments for genetic diseases. The company's lead programs, NTLA-2001 and NTLA-2002, target transthyretin ...